Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Joon Young | - |
dc.contributor.author | Noh, Ji Yun | - |
dc.contributor.author | Choi, Won Suk | - |
dc.contributor.author | Cheong, Hee Jin | - |
dc.contributor.author | Kim, Woo Joo | - |
dc.date.accessioned | 2021-09-05T00:44:30Z | - |
dc.date.available | 2021-09-05T00:44:30Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1478-7210 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/96120 | - |
dc.description.abstract | Influenza is a major cause of substantial morbidity and mortality in humans every year. Vaccination is the main strategy to prevent influenza infection, but antiviral agents also play an important role in the control of both seasonal and pandemic influenza. During the influenza A/H1N1 pandemic in 2009, early prompt antiviral therapy may have reduced the severity of the influenza outcomes including pneumonia, hospitalization and mortality in the Republic of Korea. Since the 2009 H1N1 pandemic, there have been increasing usages of antiviral agents for the treatment of patients with seasonal influenza. Although currently rare, antiviral resistance among influenza viruses may emerge and increase with increased use of neuraminidase inhibitors. New agents with different modes of action are under investigation, including favipiravir, DAS181, nitazoxanide and broad-spectrum neutralizing monoclonal antibodies. Data are limited with respect to high-dose and combination antiviral therapies. So, clinical trials are warranted to evaluate diverse antiviral combinations that may be synergistic and less likely to induce breakthrough resistance. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | ACTING NEURAMINIDASE INHIBITOR | - |
dc.subject | HUMAN MONOCLONAL-ANTIBODY | - |
dc.subject | SIALIDASE FUSION PROTEIN | - |
dc.subject | CRITICALLY-ILL PATIENTS | - |
dc.subject | H5N1 VIRUS-INFECTIONS | - |
dc.subject | A DOUBLE-BLIND | - |
dc.subject | T-705 FAVIPIRAVIR | - |
dc.subject | DOSE OSELTAMIVIR | - |
dc.subject | GLOBAL UPDATE | - |
dc.subject | DAS181 | - |
dc.title | Antiviral therapy in seasonal influenza and 2009 H1N1 pandemic influenza: Korean experiences and perspectives | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Joon Young | - |
dc.contributor.affiliatedAuthor | Noh, Ji Yun | - |
dc.contributor.affiliatedAuthor | Kim, Woo Joo | - |
dc.identifier.doi | 10.1586/14787210.2015.1076334 | - |
dc.identifier.scopusid | 2-s2.0-84945448542 | - |
dc.identifier.wosid | 000369915700008 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, v.13, no.11, pp.1361 - 1372 | - |
dc.relation.isPartOf | EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | - |
dc.citation.title | EXPERT REVIEW OF ANTI-INFECTIVE THERAPY | - |
dc.citation.volume | 13 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1361 | - |
dc.citation.endPage | 1372 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Microbiology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Microbiology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACTING NEURAMINIDASE INHIBITOR | - |
dc.subject.keywordPlus | HUMAN MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | SIALIDASE FUSION PROTEIN | - |
dc.subject.keywordPlus | CRITICALLY-ILL PATIENTS | - |
dc.subject.keywordPlus | H5N1 VIRUS-INFECTIONS | - |
dc.subject.keywordPlus | A DOUBLE-BLIND | - |
dc.subject.keywordPlus | T-705 FAVIPIRAVIR | - |
dc.subject.keywordPlus | DOSE OSELTAMIVIR | - |
dc.subject.keywordPlus | GLOBAL UPDATE | - |
dc.subject.keywordPlus | DAS181 | - |
dc.subject.keywordAuthor | antiviral agents | - |
dc.subject.keywordAuthor | drug resistance | - |
dc.subject.keywordAuthor | epidemics | - |
dc.subject.keywordAuthor | influenza | - |
dc.subject.keywordAuthor | Republic of Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.